Skip to main content
. 2023 Dec 6;13:1233039. doi: 10.3389/fonc.2023.1233039

Figure 4.

Figure 4

ZP3-Cancer expression is strongly enriched in tumor tissue and is cancer (sub)type enhanced. (A) ZP3-Cancer expression in tumor tissues relative to expression in respective healthy tissues (statistically significant upregulation, p < 0.0001 for all cancer types, Mann-Whitney test). Bars represent Tukey box plots (boxes are median+IQR). The shaded area marks tissues with very low ZP3-Cancer expression levels (< 1 TPM). BLCA, bladder urothelial carcinoma (n=413; healthy n=9); BRCA, breast invasive carcinoma (n=1132; healthy n=181); CESC, cervical squamous cell carcinoma (n=306; healthy n=10); COAD, colorectal adenocarcinoma (n=502; healthy n=308); ESCA, esophageal carcinoma (182; healthy n=655); HNSC, head-neck squamous cell carcinoma (n=520; healthy n=55); KIRC, kidney renal clear cell carcinoma (n=543; healthy n=28); KIRP, kidney renal papillary cell carcinoma (n=289; healthy n=28); LUAD, lung adenocarcinoma (n=539; healthy n=295); LUSC, lung squamous cell carcinoma (n=501; healthy n=295); MESO, mesothelioma (n=87; healthy n=295); OVCA, ovarian carcinoma (n=428; healthy n=88); PRAD, prostate adenocarcinoma (n=504; healthy n=100); READ, rectal adenocarcinoma (n=163; healthy n=308); UCEC, uterine corpus endometrial carcinoma (n=557; healthy n=79); UCS, uterine carcinosarcoma (n=57; healthy n=79); Healthy other n=5673. The same healthy tissue cohorts were used for COAD and READ (n=308), KIRC and KIRP (n=28), LUAD, LUSC and MESO (n=295), and UCEC and UCS (n=79). (B) ZP3-Cancer expression level distribution among the different cancer (sub)types. Tumors were categorized according to three expression level categories, with a stringent cut-off of 5 TPM for low expression. Cancer (sub)types are arranged in descending order of the % of samples with highest ZP3-Cancer expression (> 10 TPM). BRCA-TNBC, triple negative breast invasive carcinoma; BRCA-ER+, estrogen receptor positive breast invasive carcinoma; BRCA-HER2+, human epidermal growth factor receptor 2 positive (amplified) breast invasive carcinoma. The number of samples are indicated between brackets.